Suven Life Sciences Limited has informed the Exchange regarding a press release dated January 08, 2025, titled "Suven Life Sciences Announces First Subjects Dosed in Phase-1 Clinical Trial of SUVN-I6107, a True Muscarinic M1 Positive Allosteric Modulator (M1 PAM) for the Treatment of Cognitive Disorders".